EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Heterogeneity of Treatment Effects of Hydrocortisone by Risk of Bronchopulmonary Dysplasia or Death Among Extremely Preterm Infants in the National Institute of Child Health and Human Development Neonatal Research Network Trial

Samuel J Gentle, Matthew A Rysavy, Lei Li, Matthew M Laughon, Ravi M Patel, Erik A Jensen, Susan Hintz, Namasivayam Ambalavanan, Waldemar A Carlo, Kristi Watterberg, National Institute of Child Health and Human Development Neonatal Research Network

JAMA Network Open · 2023

DOI: 10.1001/jamanetworkopen.2023.15315 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, 2023. Verfasst von Samuel J Gentle und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Alabama at Birmingham. Hauptthemen laut MEDLINE: Hydrocortisone, Bronchopulmonary Dysplasia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Extremely preterm infants who develop bronchopulmonary dysplasia (BPD) are at a higher risk for adverse pulmonary and neurodevelopmental outcomes. In the National Institute of Child Health and Human Development Neonatal Research Network (NICHD NRN) Hydrocortisone Trial, hydrocortisone neither reduced rates of BPD or death nor increased rates of neurodevelopmental impairment (NDI) or death.

Objective

To determine whether estimated risk for grades 2 to 3 BPD or death is associated with the effect of hydrocortisone on the composite outcomes of (1) grades 2 to 3 BPD or death and (2) moderate or severe NDI or death. Design, Setting, and Participants This secondary post hoc analysis used data from the NICHD NRN Hydrocortisone Trial, which was a double-masked, placebo-controlled, randomized clinical trial conducted in 19 US academic centers. The NICHD HRN Hydrocortisone Trial enrolled infants born at a gestational age of less than 30 weeks who received mechanical ventilation for at least 7 days, including at the time of enrollment, and who were aged 14 to 28 postnatal days. Infants were enrolled between August 22, 2011, and February 4, 2018, with follow-up between 22 and 26 months of corrected age completed on March 29, 2020. Data were analyzed from September 13, 2021, to March 25, 2023.

Intervention

Infants were randomized to 10 days of hydrocortisone or placebo treatment. Main Outcomes and Measures Infants’ baseline risk of grades 2 to 3 BPD or death was estimated using the NICHD Neonatal BPD Outcome Estimator. Differences in absolute and relative treatment effects by baseline risk were evaluated using interaction terms in models fitted to the efficacy outcome of grades 2 to 3 BPD or death and the safety outcome of moderate or severe NDI or death by follow-up.

Results

Among the 799 infants included in the analysis (421 boys [52.7%]), the mean (SD) gestational age was 24.9 (1.5) weeks, and the mean (SD) birth weight was 715 (167) g. The mean estimated baseline risk for grades 2 to 3 BPD or death was 54% (range, 18%-84%) in the study population. The interaction between treatment group and baseline risk was not statistically significant on a relative or absolute scale for grades 2 to 3 BPD or death; the size of the effect ranged from a relative risk of 1.13 (95% CI, 0.82-1.55) in quartile 1 to 0.94 (95% CI, 0.81-1.09) in quartile 4. Similarly, the interaction between treatment group and baseline risk was not significant on a relative or absolute scale for moderate or severe NDI or death; the size of the effect ranged from a relative risk of 1.04 (95% CI, 0.80-1.36) in quartile 1 to 0.99 (95% CI, 0.80-1.22) in quartile 4. Conclusions and Relevance In this secondary analysis of a randomized clinical trial, the effect of hydrocortisone vs placebo was not appreciably modified by baseline risk for grades 2 to 3 BPD or death. Trial Registration ClinicalTrials.gov Identifier: NCT01353313

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydrocortisoneBronchopulmonary DysplasiaInfantMaleUnited StatesChildInfant, NewbornHumansInfant, Extremely PrematureNational Institute of Child Health and Human Development (U.S.)Respiration, Artificial

Substanzen

Hydrocortisone

Autor:innen und Institutionen

  • Department of Pediatrics, University of Alabama at Birmingham.
  • Department of Pediatrics, University of Texas Health Science Center at Houston.
  • Statistics and Epidemiology Division, RTI International, Research Triangle Park, North Carolina.
  • Department of Pediatrics, University of North Carolina at Chapel Hill.
  • Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, Georgia.
  • Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

Förderung

  • NHLBI NIH HHS
  • NICHD NIH HHS

Zitieren

APA

Gentle, S. J., Rysavy, M. A., Li, L., Laughon, M. M., Patel, R. M., Jensen, E. A., Hintz, S., Ambalavanan, N., Carlo, W. A., Watterberg, K., & National Institute of Child Health and Human Development Neonatal Research Network (2023). Heterogeneity of Treatment Effects of Hydrocortisone by Risk of Bronchopulmonary Dysplasia or Death Among Extremely Preterm Infants in the National Institute of Child Health and Human Development Neonatal Research Network Trial. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.15315

Vancouver

Gentle SJ, Rysavy MA, Li L, Laughon MM, Patel RM, Jensen EA, et al. Heterogeneity of Treatment Effects of Hydrocortisone by Risk of Bronchopulmonary Dysplasia or Death Among Extremely Preterm Infants in the National Institute of Child Health and Human Development Neonatal Research Network Trial. JAMA Network Open. 2023. doi:10.1001/jamanetworkopen.2023.15315

BibTeX
@article{Gentle2023,
  author = {Gentle, Samuel J and Rysavy, Matthew A and Li, Lei and Laughon, Matthew M and Patel, Ravi M and Jensen, Erik A and Hintz, Susan and Ambalavanan, Namasivayam and Carlo, Waldemar A and Watterberg, Kristi and National Institute of Child Health and Human Development Neonatal Research Network, National Institute of Child Health and Human Development Neonatal Research Network},
  title = {Heterogeneity of Treatment Effects of Hydrocortisone by Risk of Bronchopulmonary Dysplasia or Death Among Extremely Preterm Infants in the National Institute of Child Health and Human Development Neonatal Research Network Trial},
  journal = {JAMA Network Open},
  year = {2023},
  doi = {10.1001/jamanetworkopen.2023.15315}
}
Kostenlos starten →